Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping
Hans-Peter Beck, Rahel Wampfler, Nick Carter, Gavin Koh, Lyda Osorio, Ronnatrai Rueangweerayut, Srivcha Krudsood, Marcus V Lacerda, Alejandro Llanos-Cuentas, Stephan Duparc, Justin P Rubio, Justin A Green
JOURNAL OF INFECTIOUS DISEASES | OXFORD UNIV PRESS INC | Published : 2016
UNLABELLED: Prevention of relapse of Plasmodium vivax infection is a key treatment goal in malaria. Use of P. vivax genotyping in a multicenter, double-blind, randomized, placebo-controlled phase 2b study in Peru, India, Thailand, and Brazil allowed determination of genetically heterologous or homologous P. vivax infection recurrence following receipt of chloroquine plus one of 4 doses of tafenoquine (50, 100, 300, or 600 mg) or chloroquine plus primaquine, compared with receipt of chloroquine alone. The antihypnozoite efficacy of tafenoquine was evident as a reduction in homologous recurrences of P. vivax infection as drug doses were increased. No clear dose-response pattern was evident for..View full abstract
This work was supported by GlaxoSmithKline, Medicines for Malaria Venture.